Long non‑coding RNA RP11‑400N13.3 promotes the progression of colorectal cancer by regulating the miR‑4722‑3p/P2RY8 axis

Abstract

Accumulating evidence has shown that long non-coding RNAs (lncRNAs) play significant roles in the development and progression of many types of cancer including colorectal cancer. RP11-400N13.3 is a novel lncRNA discovered recently and its biological function and underlying mechanism in colorectal cancer remain elusive. This study aimed to reveal the relationship between RP11-400N13.3 and colorectal cancer. Our results demonstrated that the expression of RP11-400N13.3 was significantly upregulated in both colorectal cancer tissues and cell lines as compared to normal adjacent tissues and normal colonic epithelial cells by RT-qPCR, respectively. Upregulation of RP11-400N13.3 was found to be correlated with a poor overall survival rate. Functional studies revealed that RP11-400N13.3 facilitated the proliferation, migration, invasion and tumor growth of colorectal cancer cells while inhibiting the apoptosis of cancer cells in vitro and in vivo. We also observed that RP11-400N13.3 serves as a sponge for miR-4722-3p, and that P2Y receptor family member 8 (P2RY8) was predicted to be a target of miR-4722-3p by bioinformatics analysis. Western blot assay indicated that the expression of P2RY8 was negatively or positively regulated by miR-4722-3p or RP11-400N13.3. In addition, rescue experiments revealed that RP11-400N13.3 promoted proliferation, migration and invasion by directly regulating the expression of miR-4722-3p and P2RY8. In conclusion, our results revealed that RP11-400N13.3 promoted colorectal cancer progression via modulating the miR-4722-3p/P2RY8 axis, thus suggesting RP11-400N13.3 as a potential therapeutic target for the treatment of colorectal cancer.

Suppression of small nucleolar RNA host gene 8 (SNHG8) inhibits the progression of colorectal cancer cells

“…However, majority of the CRC cases are diagnosed in advanced distant metastatic stages with frustrating outcomes [ 17 ]. Despite the advances in CRC treatment protocols, the prognosis did not reach to the satisfactory level due to lack of reliable biomarkers and poor understanding of the underlying pathophysiological mechanism [ 18 ]. In recent years, rapid development of genomics technology focused on the potential role of lncRNAs to establish a new diagnostic and prognostic biomarkers for CRC patients [ 2 , 7 , 9 , 19 , 20 ].…”

Identification of EMT-Related lncRNAs as Potential Prognostic Biomarkers and Therapeutic Targets for Pancreatic Adenocarcinoma

“…From 268 PAAD patients, we identified 33 EMT-related prognostic lncRNAs, eleven of which were included in the EMT-LPS. Yang et al uncovered that RP11-400N13.3 reacts as an oncogenic lncRNA in colorectal cancer, and by modulating the miR-4722-3p/P2RY8 axis, it can accelerate colorectal cancer progression [ 31 ]. LINC00152 was firstly found overexpressed in gastric cancer and acted as an oncogene in gliomas and liver, lung, and colorectal cancer [ 32 – 34 ].…”

Identification of EMT-Related lncRNAs as a Potential Prognostic Biomarker and Therapeutic Targets for Pancreatic Adenocarcinoma

“…We identi ed 33 EMT-related prognostic lncRNAs from 268 PAAD patients, and eleven of them were included in the EMT-LPS. Yang et al uncovered that RP11-400N13.3 reacts as an oncogenic lncRNA in colorectal cancer, and can accelerate colorectal cancer progression via modulating the miR-4722-3p/P2RY8 axis [29]. LINC00152 was rstly found over expressed in gastric cancer and served as an oncogene in gliomas, liver, lung, and colorectal cancer [30][31][32].…”